439811-37-7

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-4-(4-BROMO-BENZOYL)-PIPERIDINE is used as a synthetic intermediate for the development of various pharmaceutical drugs. Its unique structure allows for the creation of new compounds with potential therapeutic properties, contributing to drug discovery and innovation.
Used in Organic Chemistry Research:
In the field of organic chemistry, 1-BOC-4-(4-BROMO-BENZOYL)-PIPERIDINE is utilized as a versatile building block for the synthesis of complex organic compounds. The BOC protecting group and the 4-(4-bromo-benzoyl) substituent provide opportunities for selective reactions and functionalization, facilitating the exploration of novel chemical pathways and the creation of advanced organic molecules.
Used in Chemical Modification and Functionalization:
1-BOC-4-(4-BROMO-BENZOYL)-PIPERIDINE is employed as a starting material for chemical modification and functionalization, enabling the attachment of various functional groups to the molecule. This process enhances the compound's properties and potential applications, making it suitable for a wide range of uses in different industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C17H22BrNO3/c1-17(2,3)22-16(21)19-10-8-13(9-11-19)15(20)12-4-6-14(18)7-5-12/h4-7,13H,8-11H2,1-3H3

Upstream product

• 203186-01-0 1-[4-(4-bromobenzoyl)piperidin-1-yl]-2,2,2-trifluoroethanone 
• 746550-66-3 (4-bromo-phenyl)-piperidin-4-yl-methanone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1046478-89-0 tert-butyl 4-(p-tolylsulfonylhydrazono)-piperidine-1-carboxylate 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 847614-88-4 4-[amino-(4-bromo-phenyl)-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 903899-02-5 4-[(4-bromo-phenyl)-(5,6-dichloro-1H-benzoimidazol-2-yl)-hydroxy-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 903899-03-6 4-[(4-bromo-phenyl)-(5,6-difluoro-1H-benzoimidazol-2-yl)-hydroxy-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 846049-61-4 4-[(4-bromo-phenyl)-(5,6-difluoro-1H-benzoimidazol-2-yl)-methylene]-piperidine-1-carboxylic acid tert-butyl ester 
• 846049-02-3 4'-[(5,6-difluoro-1H-benzoimidazol-2-yl)-piperidin-4-ylidene-methyl]-biphenyl-3-carbonitrile 
• 847614-89-5 4-[amino-(3'-cyano-biphenyl-4-yl)-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 847614-93-1 4'-{[(6-chloro-5-fluoro-1H-benzoimidazol-2-ylmethyl)-amino]-piperidin-4-yl-methyl}-biphenyl-3-carbonitrile 
• 847614-90-8 4-[[(6-chloro-5-fluoro-1H-benzoimidazol-2-ylmethyl)-amino]-(3'-cyano-biphenyl-4-yl)-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 847614-80-6 4-[(4-bromophenyl)hydroxymethyl]piperidine-1-carboxylic acid t-butyl ester 
• 846049-55-6 C₃₀H₄₀BrCl₂N₃O₄Si 
• 1464157-44-5 tert-butyl 4-(4-(3-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl)benzoyl)piperidine-1-carboxylate 
• 1464157-48-9 4-(6-(4-(piperidine-4-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464152-12-2 4-(6-(4-(hydroxy(piperidin-4-yl)methyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464152-04-2 4-(6-(4-(hydroxy(piperidin-4-yl)methyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 

Relevant academic research and scientific papers

1,4-DICARBONYL-PIPERIDYL DERIVATIVES

Compounds of the formula I in which Z, W, Q, R and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine c

BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

Preparation of unsymmetrical ketones from tosylhydrazones and aromatic aldehydes via formyl C-H bond insertion

Preparation of ketones by insertion of diazo compounds into the formyl C-H bond of an aldehyde is an attractive procedure, but use of structurally diverse diazo compounds is hampered by preparation and safety issues. A convenient procedure for the synthesis of unsymmetrical ketones from bench-stable tosylhydrazones and aryl aldehydes is reported. The procedure can be performed in one pot from the parent carbonyl compound and needs only a base, with no additional promoters being required.

BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases

2-Substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention discloses compounds of formula I wherein Ar, Y, m, n, R1 and R4 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention discloses compounds of formula I wherein Ar, X, R1 and R11 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In